BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34268412)

  • 1. The prognostic landscape of tumor-infiltrating immune cells in lung squamous cell carcinoma.
    Guo L; Yi J; Liu M; Li J
    Ann Transl Med; 2021 May; 9(9):799. PubMed ID: 34268412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analyses of a CD8
    Chen L; Weng Y; Cui X; Li Q; Peng M; Song Q
    BMC Bioinformatics; 2023 Jun; 24(1):238. PubMed ID: 37280525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing.
    Yang L; Wei S; Zhang J; Hu Q; Hu W; Cao M; Zhang L; Wang Y; Wang P; Wang K
    J Transl Med; 2022 Aug; 20(1):364. PubMed ID: 35962453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and validation of a tumor mutational burden and immune-related prognostic model for predicting the prognosis of patients with lung squamous cell carcinoma.
    Zhou Y; Xu M; Zhao K; Liu B
    J Thorac Dis; 2023 Mar; 15(3):1319-1334. PubMed ID: 37065576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A robust signature associated with patient prognosis and tumor immune microenvironment based on immune-related genes in lung squamous cell carcinoma.
    Zhou H; Zhang H; Shi M; Wang J; Huang Z; Shi J
    Int Immunopharmacol; 2020 Nov; 88():106856. PubMed ID: 32777677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of a prognostic signature for patients with advanced lung squamous cell carcinoma based on tumor-infiltrating immune cells.
    Wu D; Zhang H; Huang H; Li X; Liu X; Liu H; Chen J
    Transl Cancer Res; 2023 Oct; 12(10):2706-2716. PubMed ID: 37969402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune signature of T follicular helper cells predicts clinical prognostic and therapeutic impact in lung squamous cell carcinoma.
    Xu F; Zhang H; Chen J; Lin L; Chen Y
    Int Immunopharmacol; 2020 Apr; 81():105932. PubMed ID: 31836430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Analysis of Immune Implication and Prognostic Value of
    Zeng Y; Zhang Z; Chen H; Fan J; Yuan W; Li J; Zhou S; Liu W
    Front Oncol; 2021; 11():798425. PubMed ID: 35047409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a novel immune-related prognostic model in lung squamous cell carcinoma.
    Liu Z; Wan Y; Qiu Y; Qi X; Yang M; Huang J; Zhang Q
    Int J Med Sci; 2020; 17(10):1393-1405. PubMed ID: 32624696
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification and validation of an individualized prognostic signature of lung squamous cell carcinoma based on ferroptosis-related genes.
    Diao X; Guo C; Liu L; Wang G; Li S
    Thorac Cancer; 2021 Dec; 12(23):3236-3247. PubMed ID: 34672420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Li Y; Zheng P; Zhan X
    Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of tumour-infiltrating myeloid subsets associated with overall survival in lung squamous cell carcinoma.
    Lu J; Duan Y; Liu P; He X; Yang Y; Zhang R; Weng L
    J Pathol; 2023 Jan; 259(1):21-34. PubMed ID: 36178315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of a Two-Gene Immunogenomic-Related Prognostic Signature in Lung Squamous Cell Carcinoma.
    Zhang X; Xiao J; Fu X; Qin G; Yu M; Chen G; Li X
    Front Mol Biosci; 2022; 9():867494. PubMed ID: 35463955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Integrative Analysis Identifying RAB40C as an Oncogenic Immune Protein and Prognostic Marker of Lung Squamous Cell Carcinoma.
    Wu H; Dong X; Liao L; Huang L
    Pharmgenomics Pers Med; 2022; 15():525-537. PubMed ID: 35645578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer.
    Liu X; Wu S; Yang Y; Zhao M; Zhu G; Hou Z
    Biomed Pharmacother; 2017 Nov; 95():55-61. PubMed ID: 28826097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analyses of the heterogeneity and prognostic significance of tumor-infiltrating immune cells in non-small-cell lung cancer: Development and validation of an individualized prognostic model.
    Pang Z; Chen X; Wang Y; Wang Y; Yan T; Wan J; Du J
    Int Immunopharmacol; 2020 Sep; 86():106744. PubMed ID: 32623229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classification of the immune microenvironment associated with 12 cell death modes and construction of a prognostic model for squamous cell lung cancer.
    Bin Y; Ding P; Liu L; Tong F; Dong X
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9051-9070. PubMed ID: 37169931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LIMK2 Is a Novel Prognostic Biomarker and Correlates With Tumor Immune Cell Infiltration in Lung Squamous Cell Carcinoma.
    Su Y; Xu B; Shen Q; Lei Z; Zhang W; Hu T
    Front Immunol; 2022; 13():788375. PubMed ID: 35273591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a seven-miRNA signature as prognostic biomarker for lung squamous cell carcinoma.
    Gao X; Wu Y; Yu W; Li H
    Oncotarget; 2016 Dec; 7(49):81670-81679. PubMed ID: 27835574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune cell landscape analysis reveals prognostic immune cells and its potential mechanism in squamous cell lung carcinoma.
    Wang Y; Guo J
    PeerJ; 2020; 8():e9996. PubMed ID: 33083119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.